Protect Your Bank Account Before It’s Too Late

For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …

Stop right now and do these 3 things to protect yourself

Peter Heerma Biography and Net Worth

Insider of Travere Therapeutics

Peter Heerma has served as chief commercial officer at Travere Therapeutics since October 2019. He is responsible for leading the company’s commercial organization including commercialization strategy for approved products and pre-commercial planning for pipeline programs. He brings more than 20 years of global experience launching best-in-class therapies across therapeutic areas, managing pipeline and on-market product portfolios, and leading commercial and cross-functional teams at a number of top biopharmaceutical organizations.

Prior to joining Travere Therapeutics, Mr. Heerma served as global product general manager for oncology and cardiovascular products at Amgen where he led four cross-functional global product leadership teams with a revenue base exceeding $7 billion in 2018. He has also held various commercial leadership roles at AbbVie and Abbott Laboratories, most recently serving as AbbVie’s senior director of portfolio strategy for hepatology and nephrology. Prior to that, he served as senior director and asset team lead for HCV, diabetic nephropathy, and neuroscience development projects at AbbVie. While at Abbott Laboratories, Mr. Heerma held the titles of director of commercial strategy for renal care, international marketing director for Zemplar, business unit manager of hospital products, and product manager for obesity and cardiovascular products.

He holds a Master of Science in European business administration and business law from the Lund University in Sweden and a Bachelor of Science in retail management and marketing from Stenden University in the Netherlands.

What is Peter Heerma's net worth?: The estimated net worth of Peter Heerma is at least $571,147.22 as of February 1st, 2024. Mr. Heerma owns 99,503 shares of Travere Therapeutics stock worth more than $571,147 as of April 24th. This net worth evaluation does not reflect any other assets that Mr. Heerma may own. Additionally, Mr. Heerma receives a salary of $742,370.00 as Insider at Travere Therapeutics. Learn More about Peter Heerma's net worth.
How old is Peter Heerma?: Mr. Heerma is currently 52 years old. There are 5 older executives and no younger executives at Travere Therapeutics. The oldest executive at Travere Therapeutics is Dr. William E. Rote Ph.D., Senior VP and Head of Research & Development, who is 61 years old. Learn More on Peter Heerma's age.
What is Peter Heerma's salary?: As the Insider of Travere Therapeutics, Inc., Mr. Heerma earns $742,370.00 per year. There are 2 executives that earn more than Mr. Heerma. The highest earning executive at Travere Therapeutics is Dr. Eric M. Dube Ph.D., President, CEO & Director, who commands a salary of $1,400,000.00 per year. Learn More on Peter Heerma's salary.
How do I contact Peter Heerma?: The corporate mailing address for Mr. Heerma and other Travere Therapeutics executives is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. Travere Therapeutics can also be reached via phone at (888) 969-7879 and via email at [email protected]. Learn More on Peter Heerma's contact information.
Has Peter Heerma been buying or selling shares of Travere Therapeutics?: Peter Heerma has not been actively trading shares of Travere Therapeutics during the last ninety days. Most recently, Peter Heerma sold 4,195 shares of the business's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $8.53, for a transaction totalling $35,783.35. Following the completion of the sale, the insider now directly owns 99,503 shares of the company's stock, valued at $848,760.59. Learn More on Peter Heerma's trading history.
Who are Travere Therapeutics' active insiders?: Travere Therapeutics' insider roster includes Steve Aselage (Director), Sandra Calvin (CAO), Laura Clague (CFO), Eric Dube (CEO), Peter Heerma (Insider), Elizabeth Reed (SVP), Noah Rosenberg (Insider), and William Rote (SVP). Learn More on Travere Therapeutics' active insiders.
Are insiders buying or selling shares of Travere Therapeutics?: During the last year, insiders at the sold shares 19 times. They sold a total of 61,633 shares worth more than $592,310.91. The most recent insider tranaction occured on April, 11th when CFO Christopher R Cline sold 54 shares worth more than $363.96. Insiders at Travere Therapeutics own 4.1% of the company. Learn More about insider trades at Travere Therapeutics.
Information on this page was last updated on 4/11/2024.

Peter Heerma Insider Trading History at Travere Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/1/2024	Sell	4,195	$8.53	$35,783.35	99,503
1/23/2024	Sell	1,559	$9.07	$14,140.13	78,698
10/3/2023	Sell	3,091	$8.25	$25,500.75	80,257
2/1/2023	Sell	1,779	$21.75	$38,693.25	82,069
1/24/2023	Sell	1,550	$21.90	$33,945.00	63,598
10/4/2022	Sell	3,042	$25.68	$78,118.56	65,148
1/31/2022	Sell	1,125	$27.40	$30,825.00
8/17/2021	Sell	1,407	$17.12	$24,087.84

Peter Heerma Buying and Selling Activity at Travere Therapeutics

Travere Therapeutics Company Overview

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Today's Range

Now: $5.74

$5.71

$5.96

50 Day Range

MA: $7.46

$5.72

$8.74

2 Week Range

Now: $5.74

$5.25

$22.75

Volume

1,244,602 shs

Average Volume

1,240,115 shs

Market Capitalization

$436.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58

Protect Your Bank Account Before It’s Too Late

From Weiss Ratings | Ad

For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …

Stop right now and do these 3 things to protect yourself

Peter Heerma Biography and Net Worth

What is Peter Heerma's net worth?

How old is Peter Heerma?

What is Peter Heerma's salary?

How do I contact Peter Heerma?

Has Peter Heerma been buying or selling shares of Travere Therapeutics?

Who are Travere Therapeutics' active insiders?

Are insiders buying or selling shares of Travere Therapeutics?